Skip to main content
Division of Cancer Prevention
Division of Cancer Prevention

Search form

Making cancer prevention possible

Main menu

  • Home
  • Major Programs
    • Cancer Prevention Fellowship Program (CPFP)
    • Early Detection Research Network (EDRN)
    • NCI Community Oncology Research Program (NCORP)
    • Alliance of Glycobiologists for Cancer Research
    • Barrett's Esophagus Translational Research Network (BETRNet)
    • Cancer Prevention Clinical Trials Network (CP-CTNet)
    • Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
    • Cancer Screening Research Network (CSRN)
    • Cancer Treatment Tolerability Consortium
    • Consortium for Imaging and Biomarkers (CIB)
    • HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network
    • Liquid Biopsy Consortium
    • Lung Cancer Screening Image Library
    • Multi-Cancer Detection (MCD) Research
    • NCI Cervical Cancer ‘Last Mile’ Initiative
    • Pancreatic Cancer Detection Consortium (PCDC)
    • Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
    • PREVENT Cancer Preclinical Drug Development Program (PREVENT)
    • Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)
    • Small Cell Lung Cancer (SCLC) Consortium
    • Supportive Care and Symptom Management
    • Translational and Basic Science Research in Early Lesions (TBEL) Program
    • Translational Liver Cancer (TLC) Consortium
    • US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet)
  • Research Groups
    • Biometry
    • Breast and Gynecologic Cancer
    • Cancer Biomarkers
    • Chemopreventive Agent Development
    • Community Oncology and Prevention Trials
    • Early Detection
    • Gastrointestinal and Other Cancers
    • Lung and Upper Aerodigestive Cancer
    • Nutritional Science
    • Prostate and Urologic Cancer
  • Clinical Trials
    • Clinical Trials Search
    • Landmark Trials
    • Clinical Trials Management
    • Why I Joined a Clinical Trial
  • Funding & Grants
    • Funding Opportunities
    • Funded Grants
    • Grantsmanship Resources
  • Resources
    • Publication Search
    • Biorepositories
    • Cancer Data Access System
  • News & Events
    • News
      • CP-CTNet Newsletter - September 2022
    • Blog
    • Meetings and Events
    • Videos and Webinars
    • Infographics
  • About DCP
    • Scientific Scope
    • Commemoration of the 50th Anniversary of the National Cancer Act
    • Director
    • DCP Leadership
    • History and Timeline
    • Historical Resources
    • Staff Directory

You are here

  1. Home
  2.   »  Major Programs
  3.   »  Early Detection Research Network (EDRN)

Major Programs

  • Alliance of Glycobiologists for Cancer Research
  • Barrett's Esophagus Translational Research Network (BETRNet)
  • Cancer Prevention Clinical Trials Network (CP-CTNet)
  • Cancer Prevention Fellowship Program (CPFP)
  • Consortium for Imaging and Biomarkers (CIB)
  • Early Detection Research Network (EDRN)
    • Active Grants
    • Funding Opportunities
  • Liquid Biopsy Consortium
  • NCI Community Oncology Research Program (NCORP)
  • Pancreatic Cancer Detection Consortium (PCDC)
  • Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
  • PREVENT Cancer Preclinical Drug Development Program (PREVENT)
  • Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
  • Small Cell Lung Cancer (SCLC) Consortium
  • Supportive Care and Symptom Management
  • Translational Liver Cancer (TLC) Consortium
  • Active Grants
  • Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
  • Cancer Screening Research Network (CSRN)
  • Cancer Treatment Tolerability Consortium
  • HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network
  • Multi-Cancer Detection (MCD) Research
  • NCI Cervical Cancer ‘Last Mile’ Initiative
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Small Cell Lung Cancer (SCLC) Consortium
  • Taking Advantage of the Transportation Processes from Inside to Outside the Cell to Detect Cancer
  • Translational and Basic Science Research in Early Lesions (TBEL) Program
  • US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet)

Early Detection Research Network (EDRN)

The Early Detection Research Network (EDRN) is a collaborative program that maintains comprehensive infrastructure and resources critical to the discovery, development and validation of biomarkers for cancer risk and early detection.

The DCP Cancer Biomarkers Research Group administers this program.

Visit the EDRN website

The program comprises a public/private sector consortium to accelerate the development of biomarkers that can improve medical practice, ensure data reproducibility and integrity, and adapt to the changing landscape of biomarker science.

Active Grants

Funding Opportunities

Early Detection Research Network Marks 20 Years

This month, the Early Detection Research Network (EDRN) marks its 20th anniversary. The National Cancer Institute (NCI) launched the network in 2000 with the goal of identifying and harnessing biomarkers as a way of detecting cancer at earlier stages. Today, the network comprises more than 300 researchers at cancer centers around the United States.

Identifying New Biomarkers to Detect Lung Cancer Earlier

Lung cancer, the leading cause of cancer deaths worldwide killing 1.8 million people each year, is often diagnosed at an advanced stage when the chances for a cure are limited.

Follow us at:

@NCIPrevention

@NCISymptomMgmt

@NCICastle

The National Cancer Institute

Policies

DCP Home

Contact DCP

Policies

Disclaimer Policy

Accessibility

FOIA

HHS Vulnerability Disclosure

NCI's PDQ® Evidence-based Summaries

Cancer Prevention

Screening/Detection/Testing for Cancer

Supportive and Palliative Care

General Information

Cancer Prevention, Specific Cancers, Clinical Trials

Cancer Screening Topics For People Who Have No Symptoms

Managing The Side Effects of Cancer and Its Treatment

Coping With Cancer

US Preventive Services Task Force Recommendations About Cancer

NIH COVID-19 Resources

U.S. Department of Health and Human Services  |  National Institutes of Health  |  National Cancer Institute  |  USA.gov

NIH…Turning Discovery Into Health®